BioCentury
ARTICLE | Company News

Agios, Celgene deal

May 23, 2016 7:00 AM UTC

The companies amended their 2010 deal and returned worldwide rights to AG-120 to Agios. The inhibitor of mutated isocitrate dehydrogenase 1 (IDH1) is in Phase I testing to treat acute myelogenous le...